vida: extract claims from 2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
- Source: inbox/queue/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md - Domain: health - Claims: 2, Entities: 0 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
This commit is contained in:
Teleo Agents
parent
46d554812d
commit
846e63b4be
6 changed files with 70 additions and 16 deletions
|
|
@ -0,0 +1,20 @@
|
|||
---
|
||||
type: claim
|
||||
domain: health
|
||||
description: Regulatory oversight gap where large-scale trials failed to detect clinically significant psychiatric side effect due to measurement design, not sample size
|
||||
confidence: experimental
|
||||
source: Washington Post, April 2026 investigation
|
||||
created: 2026-05-06
|
||||
title: Anhedonia is absent from all GLP-1 adverse event labels despite 54,000+ trial participants because trials were not designed to measure hedonic outcomes
|
||||
agent: vida
|
||||
sourced_from: health/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md
|
||||
scope: structural
|
||||
sourcer: Washington Post Health
|
||||
supports: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge"]
|
||||
challenges: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
|
||||
related: ["clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant"]
|
||||
---
|
||||
|
||||
# Anhedonia is absent from all GLP-1 adverse event labels despite 54,000+ trial participants because trials were not designed to measure hedonic outcomes
|
||||
|
||||
The drug has been studied in 54,000+ trial participants, yet anhedonia is NOT currently listed as an adverse drug reaction or warning in any GLP-1 label. Doctors quoted in the investigation say 'reports of anhedonia are not widespread' but cases are accumulating in clinical practice. The absence from labeling despite massive trial populations indicates a measurement design failure: clinical trials for metabolic drugs do not systematically assess hedonic capacity using validated instruments like the Snaith-Hamilton Pleasure Scale (SHAPS). The article describes a clinical phenomenon without mentioning any systematic measurement tool, suggesting the field has not operationalized this as a monitorable adverse effect. This represents a regulatory oversight gap where trial design assumptions (focus on metabolic endpoints, weight loss, cardiovascular outcomes) systematically exclude psychiatric outcomes that only become visible in post-market surveillance. The ~100 cases being compiled by researchers represent early-stage formal characterization of a phenomenon that was invisible to the regulatory approval process.
|
||||
|
|
@ -0,0 +1,19 @@
|
|||
---
|
||||
type: claim
|
||||
domain: health
|
||||
description: Clinical case series documents rapid reversal of emotional blunting with dose reduction, establishing reversibility timeframe and dose-response relationship
|
||||
confidence: experimental
|
||||
source: Washington Post, multi-institution researcher compilation of ~100 cases from thousands treated
|
||||
created: 2026-05-06
|
||||
title: GLP-1-induced anhedonia is dose-dependent and resolves in most cases within weeks of dose reduction, suggesting tonic dopamine suppression rather than permanent neurological change
|
||||
agent: vida
|
||||
sourced_from: health/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md
|
||||
scope: causal
|
||||
sourcer: Washington Post Health
|
||||
challenges: ["food-noise-quiet-narrative-reframes-glp1-anhedonia-as-liberation"]
|
||||
related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "food-noise-quiet-narrative-reframes-glp1-anhedonia-as-liberation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement"]
|
||||
---
|
||||
|
||||
# GLP-1-induced anhedonia is dose-dependent and resolves in most cases within weeks of dose reduction, suggesting tonic dopamine suppression rather than permanent neurological change
|
||||
|
||||
Researchers compiling approximately 100 cases of GLP-1-induced anhedonia report that most cases resolved with dose reduction 'often as quickly as within a few weeks.' One documented case showed a patient on Zepbound (tirzepatide) 15mg weekly who reduced to 12.5mg and 'within two weeks reported feeling joy again.' The rapid reversibility timeframe (weeks, not months) suggests the mechanism is tonic suppression of dopamine signaling rather than structural neurological change or receptor downregulation, which would require longer recovery periods. The dose-dependence is demonstrated by the fact that partial dose reduction (not full discontinuation) was sufficient to restore hedonic capacity. Some persistent cases were treated with bupropion (Wellbutrin), a dopamine-enhancing antidepressant, as compensatory treatment, further supporting the dopaminergic mechanism. The proposed mechanism involves GLP-1 receptors in brainstem, lateral septum, and hypothalamus that 'tone down regions of the brain associated with pleasure.' However, animal evidence is contradictory: one lab found chronically muted dopamine responses while another found 'turbocharged' dopamine signal, indicating the precise mechanism remains unsettled.
|
||||
|
|
@ -10,20 +10,18 @@ agent: vida
|
|||
sourced_from: health/2026-05-05-ozempic-personality-anhedonia-glp1-dopamine.md
|
||||
scope: causal
|
||||
sourcer: Multiple (Washington Post, KTLA, Washington Times)
|
||||
challenges:
|
||||
- medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate-as-four-independent-methodologies-confirm
|
||||
related:
|
||||
- modernization-dismantles-family-and-community-structures-replacing-them-with-market-and-state-relationships-that-increase-individual-freedom-but-erode-psychosocial-foundations-of-wellbeing
|
||||
- modernization dismantles family and community structures replacing them with market and state relationships that increase individual freedom but erode psychosocial foundations of wellbeing
|
||||
- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
|
||||
- glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
|
||||
- hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement
|
||||
supports:
|
||||
- Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm
|
||||
reweave_edges:
|
||||
- Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm|supports|2026-05-06
|
||||
challenges: ["medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate-as-four-independent-methodologies-confirm"]
|
||||
related: ["modernization-dismantles-family-and-community-structures-replacing-them-with-market-and-state-relationships-that-increase-individual-freedom-but-erode-psychosocial-foundations-of-wellbeing", "modernization dismantles family and community structures replacing them with market and state relationships that increase individual freedom but erode psychosocial foundations of wellbeing", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "food-noise-quiet-narrative-reframes-glp1-anhedonia-as-liberation"]
|
||||
supports: ["Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm"]
|
||||
reweave_edges: ["Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm|supports|2026-05-06"]
|
||||
---
|
||||
|
||||
# GLP-1 anhedonia mechanism undermines social engagement and meaning as non-clinical health determinants even while treating metabolic disease
|
||||
|
||||
Clinicians are reporting a pattern they call 'Ozempic personality' where GLP-1 patients experience reduced interest not just in food but in social activities, sex, music, and other pleasurable activities. The mechanism is the same VTA dopamine circuit suppression that makes GLP-1 effective for addiction treatment — GLP-1 receptors in brain regions governing mood, motivation, and emotional responses inadvertently affect emotional engagement when altered. Patients describe 'emotional flattening' where they still recognize positive moments but feel less excitement or connection. This creates a paradox: GLP-1 may simultaneously treat metabolic disease (the clinical 10-20% of health determinants) while undermining the motivational substrate for social engagement and meaning (the behavioral/social 80-90%). The mechanism is supported by addiction research showing GLP-1 reduces craving preconsciously, indicating reward processing changes extend beyond food. No quantitative prevalence data exists yet — this is clinical pattern recognition phase with anecdotal reports from clinicians and social media. The FDA removed the suicidal behavior warning from GLP-1 in 2026 and no anhedonia warning exists, suggesting regulatory bodies are not yet tracking this risk.
|
||||
Clinicians are reporting a pattern they call 'Ozempic personality' where GLP-1 patients experience reduced interest not just in food but in social activities, sex, music, and other pleasurable activities. The mechanism is the same VTA dopamine circuit suppression that makes GLP-1 effective for addiction treatment — GLP-1 receptors in brain regions governing mood, motivation, and emotional responses inadvertently affect emotional engagement when altered. Patients describe 'emotional flattening' where they still recognize positive moments but feel less excitement or connection. This creates a paradox: GLP-1 may simultaneously treat metabolic disease (the clinical 10-20% of health determinants) while undermining the motivational substrate for social engagement and meaning (the behavioral/social 80-90%). The mechanism is supported by addiction research showing GLP-1 reduces craving preconsciously, indicating reward processing changes extend beyond food. No quantitative prevalence data exists yet — this is clinical pattern recognition phase with anecdotal reports from clinicians and social media. The FDA removed the suicidal behavior warning from GLP-1 in 2026 and no anhedonia warning exists, suggesting regulatory bodies are not yet tracking this risk.
|
||||
|
||||
## Extending Evidence
|
||||
|
||||
**Source:** Washington Post, April 16, 2026
|
||||
|
||||
Washington Post investigation documents anhedonia extending beyond food reward to social activities, music, sex, and daily pleasures. Symptoms align with clinical anhedonia: diminished enjoyment in activities that normally bring happiness. The broad hedonic blunting affects multiple domains of social engagement, not just eating behavior.
|
||||
|
|
|
|||
|
|
@ -11,7 +11,7 @@ sourced_from: health/2025-truveta-ispor-glp1-discontinuation-reasons.md
|
|||
scope: correlational
|
||||
sourcer: Truveta Research
|
||||
supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
|
||||
related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-persistence-improves-with-specialist-care-supporting-obesity-medicine-infrastructure", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations"]
|
||||
related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-persistence-improves-with-specialist-care-supporting-obesity-medicine-infrastructure", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-eating-disorder-risk-doubles-with-prior-mental-health-history"]
|
||||
---
|
||||
|
||||
# GLP-1 discontinuation is 12 percent higher among patients with psychiatric medication history creating an access-adherence trap where highest-need populations have lowest persistence
|
||||
|
|
@ -31,3 +31,10 @@ Concurrent prescribing analysis shows OR 4.45 for suicidal ideation reports with
|
|||
**Source:** MDPI Nutrients PMC12694361
|
||||
|
||||
Review identifies eating disorder history, perfectionism, OCD traits, and emotion regulation deficits as primary risk factors for GLP-1 adverse psychiatric outcomes. This extends the psychiatric comorbidity discontinuation pattern by specifying which psychiatric phenotypes create highest risk: restrictive eating disorders and obsessive-compulsive spectrum conditions rather than psychiatric comorbidity in general.
|
||||
|
||||
|
||||
## Extending Evidence
|
||||
|
||||
**Source:** Washington Post, April 16, 2026
|
||||
|
||||
Dose-reduction reversibility of anhedonia within weeks provides clinical management pathway that may prevent full discontinuation. One patient reduced Zepbound from 15mg to 12.5mg and regained hedonic capacity within two weeks, suggesting dose titration as alternative to cessation.
|
||||
|
|
|
|||
|
|
@ -11,7 +11,7 @@ sourced_from: health/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.m
|
|||
scope: structural
|
||||
sourcer: NEDA/ANAD
|
||||
supports: ["ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
|
||||
related: ["the-mental-health-supply-gap-is-widening-not-closing", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "neda", "anad", "glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population"]
|
||||
related: ["the-mental-health-supply-gap-is-widening-not-closing", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "neda", "anad", "glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population", "glp1-eating-disorder-screening-protocol-scoff-plus-history-plus-behavioral-assessment-recommended-for-pre-treatment-risk-stratification", "glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population"]
|
||||
---
|
||||
|
||||
# GLP-1 eating disorder screening gap is structural capacity failure not clinical knowledge deficit because professional society guidance requires tri-specialist care teams unavailable in primary care settings where most prescriptions originate
|
||||
|
|
@ -73,3 +73,10 @@ Dr. DeCaro and Dr. Dennis provide clinical expert consensus that screening proto
|
|||
**Source:** STAT News, April 27, 2026
|
||||
|
||||
Expert assessment that healthcare system is 'unprepared for this coming wave' of eating disorder cases suggests infrastructure gap extends beyond screening protocols to treatment capacity. The 420,000 person projection (1.28% of potential GLP-1 user population) represents scale that would overwhelm existing eating disorder treatment infrastructure.
|
||||
|
||||
|
||||
## Supporting Evidence
|
||||
|
||||
**Source:** Washington Post, April 16, 2026
|
||||
|
||||
Anhedonia screening is similarly absent from GLP-1 prescribing practice despite accumulating clinical cases. Article describes phenomenon without mentioning validated instruments like SHAPS (Snaith-Hamilton Pleasure Scale), indicating psychiatric monitoring infrastructure has not been operationalized at prescribing scale.
|
||||
|
|
|
|||
|
|
@ -7,10 +7,13 @@ date: 2026-04-16
|
|||
domain: health
|
||||
secondary_domains: []
|
||||
format: article
|
||||
status: unprocessed
|
||||
status: processed
|
||||
processed_by: vida
|
||||
processed_date: 2026-05-06
|
||||
priority: high
|
||||
tags: [GLP-1, semaglutide, anhedonia, ozempic-personality, dopamine, reward, side-effects, dose-dependence, reversibility]
|
||||
intake_tier: research-task
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
Loading…
Reference in a new issue